The latest analysis of HAPO and HAPO FUS data indicates that, contrary to prior assumptions, a high birthweight and newborn adiposity are associated with good metabolic health in childhood.
Intravitreous aflibercept and vitrectomy with panretinal laser photocoagulation appear to have similar efficacy over 24 weeks when used for the treatment of vitreous hemorrhage from proliferative diabetic retinopathy, researchers report.
Treatment with bariatric surgery is associated with clinical and cost-saving benefits among obese people with type 2 diabetes requiring insulin, researchers report.
Acute kidney injury is common in children with diabetic ketoacidosis and is associated with circulatory volume depletion, greater acidosis, and signs of cerebral injury, US study data show.
Dapagliflozin reduces the risk for adverse renal outcomes, and also adverse cardiovascular outcomes and mortality, shows a prespecified subgroup analysis of DAPA-CKD.
An observational study suggests that prior metformin use may offer a protective effect against COVID-19 mortality in people with type 2 diabetes, but only for women.
Negative emotional experience and skill at regulating emotions are associated with diabetes distress in adults with type 1 or type 2 diabetes, researchers report.
Empagliflozin reduces the total burden of cardiovascular complications and all-cause hospitalization in people with type 2 diabetes and atherosclerosis, show data from the EMPA-REG OUTCOME trial.
People living in metropolitan cities in India have a high likelihood of developing diabetes, with a particularly elevated risk in overweight and obese individuals, research shows.
A prespecified analysis of the FIDELIO-DKD trial shows that finerenone reduces the risk for cardiovascular disease events in people with type 2 diabetes and chronic kidney disease, irrespective of whether they have pre-existing heart disease.
Starting children on an insulin pump within 6 months of type 1 diabetes diagnosis is associated with improved outcomes relative to delaying for 2 or 3 years, shows an analysis of data from the DPV registry.
Switching to fast-acting insulin aspart significantly improves glycemic control and time in glucose target range in people with type 1 diabetes using continuous glucose monitoring, data from the real-world GoBolus study show.
People with type 2 diabetes have around a fourfold increased risk for heart disease relative to those without, but having a healthy lifestyle may lessen this risk, researchers report.
The risk for cardiovascular disease is at least one-fifth higher in people with type 2 diabetes than in those without diabetes, even when risk factors are optimally controlled, study findings indicate.
The EMPATROPISM trial, which enrolled people without type 2 diabetes, shows reversal of left ventricular remodeling in patients with heart failure and reduced ejection fraction given empagliflozin rather than placebo.
A Spanish cross-sectional study suggests that a substantial proportion of people with type 2 diabetes are at very high risk for fatal cardiovascular events and could be considered as coronary artery disease equivalent.”
Cardiovascular event rates do not differ significantly among people with type 2 diabetes treated with linagliptin or glimepiride regardless of age, but those who receive linagliptin have lower risks for falls and hypoglycemia, CAROLINA trial data show.